April 8 (Reuters) - The U.S. Food and Drug Administration (FDA) declined to approve Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Monday. (Reporting by Puyaan Singh in Bengaluru; Editing by Shinjini Ganguli)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.77 USD | -0.36% | -3.38% | -4.04% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2,590 JPY | +0.95% | -1.86% | 8.74B | ||
158.3 USD | -0.85% | -3.38% | 282B | ||
27.77 USD | -0.36% | -3.38% | 1.53B | ||
0.75 USD | +4.17% | +97.37% | 894K | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.04% | 1.53B | |
+9.28% | 8.74B | |
-15.14% | 4.94B | |
+50.73% | 4.7B | |
+4.36% | 3.98B | |
-26.13% | 2.28B | |
+12.07% | 2.28B | |
+16.45% | 2.14B | |
-33.59% | 2.12B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease